Sign Out
Hepatic: Administration may be followed, in up to 10% of cases, by increases in AST and ALT enzymes, which sometimes recur on challenge.
Cholestatic hepatitis. Jaundice.
Gastrointestinal: Pseudomembranous colitis has been reported rarely with Erythromycin. Gastrointestinal disturbances such as abdominal discomfort and cramp, nausea, vomiting and diarrhoea are common after both oral and parenteral administration.
Pancreatitis (rare).
Cardiovascular: Thrombophlebitis, venous irritation. Irritation can be reduced by either slow IV injection, or preferably a small volume IV infusion.
Prolongation of the QT interval and development of ventricular arrhythmias (some of which have been fatal), including atypical ventricular tachycardia (torsades de pointes), have been reported with the intravenous administration of Erythromycin. Limited data suggest that these adverse effects may be associated with abnormally elevated serum Erythromycin concentrations following rapid administration.
Auditory/Vestibular: In very high doses, Erythromycin may cause transient perceptive deafness.
Dermatological: Mild allergic reactions, urticaria, skin eruptions, rashes with fever, and reports of erythema multiforme reaction have been noted.
Stevens-Johnson syndrome and toxic epidermal necrolysis have rarely been reported.
Skin and Subcutaneous Tissue Disorders: Frequency not known: severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) & acute generalised exanthematous pustulosis (AGEP).
Post Marketing Experience: Gastrointestinal Disorders: Infantile hypertrophic pyloric stenosis.
